Manufacturing USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns BioSpaceAlmost half of the top 100 medicines vulnerable to supply disruptions in the U.S.ManufacturingRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) BioSpace Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S. ManufacturingRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Allogene stock sails after CAR T clears residual lymphoma in early data cutNext: FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results Related Stories Manufacturing pharminent June 17, 2026 Manufacturing Eisai claims UK grant to expand manufacturing site pharminent June 15, 2026 Manufacturing FDA imposes import alert on Indian plant after inspectors flag GMP failings pharminent June 12, 2026
